NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Silence Therapeutics plc (SLN) Stock Analysis

Silence Therapeutics plc (SLN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SLN

$14.59

−$0.20 (−1.35%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SLN with… →

SLN Key Statistics

As of Sep 4, 2026
Trading
Open
$14.63
Previous Close
$14.79
Day's Range
14.42–14.79
52-Week Range
4.19–17.58
Volume
474.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.44
Valuation
Market Cap
$906.83M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1474.52
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.29
Financials (FY)
Revenue (FY)
$559.00K−98.71%
Net Income (FY)
−$88.61M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
62.15M
1-Year Return
+178.97%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
991.35K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SLN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+139.97%
2025−11.63%
2024−60.39%
2023+13.90%
2022−36.17%
2021+8.59%
2020 (partial year)+12.82%

As of September 4, 2026.

SLN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$559.00K−$88.61M−15851.9%
2024$43.26M−$45.31M−104.7%
2023$31.64M−$54.23M−171.4%
2022$21.66M−$50.33M−232.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$559.00K$344.00K−$89.75M−$88.61M−15851.9%
2024$43.26M$31.45M−$63.32M−$45.31M−104.7%
2023$31.64M$18.78M−$64.38M−$54.23M−171.4%
2022$21.66M$8.19M−$61.04M−$50.33M−232.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SLN Valuation vs Biotechnology Median

Median of 656 stocks
MetricSLNBiotechnology medianvs median
P/S ratio1474.5215.2696.6x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Silence Therapeutics plc (SLN) carries a market capitalisation of $906.83M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 88 employees.

Over the past 52 weeks the price has ranged from $4.19 to $17.58. SLN last closed at $14.59 on September 4, 2026. That is −$0.20 (−1.35%) against the previous close. The latest close sits 248.21% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $559.00K. That is −98.71% against the prior fiscal year, when revenue was $43.26M. The same year closed with a net loss of $88.61M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.29.

Across the 4 fiscal years on file, revenue moves from $21.66M in 2022 to $559.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 1,474.52 times revenue. On price-to-sales that is 96.6 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 1.44. Daily returns over the trailing 6 years annualize to a volatility of 80.3%. The trailing one-year price return is +178.97%. Across 5 years the annualized return works out at −8.74%.

Growth & Income

No dividend is on file for SLN.

2026 is still running; the price is +139.97% year to date. Across the complete calendar years on file, 2023 returned +13.90% and 2024 returned −60.39%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

Silence Therapeutics plc (SLN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Silence Therapeutics plc SLN $906.83M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Silence Therapeutics plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Silence Therapeutics plc

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Visit website →